Andrew R. Heyer, W’79, WG’79, a member of the University of Pennsylvania’s Board of Trustees, has been named chair of Penn Medicine. The post is retroactively effective from July 1, 2016. Mr. Heyer has been a member of the Penn Medicine Board and its executive committee since 2009.

David L. Cohen, chair of Penn’s Board of Trustees, said, “Andy Heyer is the ideal person to step into this role. He has a deep commitment to Penn and Penn Medicine, evidenced by the myriad roles he has assumed and committees he has served so ably as a Penn Trustee. I am looking forward to working with him in this new role.”

“We are delighted that Andy has stepped into this important role at a time when Penn Medicine has further advanced its reputation as a preeminent academic medical center,” Penn President Amy Gutmann said. “Andy is a thoughtful, strategic leader with a demonstrated dedication to Penn and Penn Medicine. His breadth of experience and commitment to Penn Medicine will help assure Penn Medicine’s continued eminence and momentum, which have grown exponentially under the leadership of Dr. J. Larry Jameson, executive vice president of Penn Medicine and dean of the Perelman School of Medicine.”

Mr. Heyer replaced Mark O. Winkelman, a senior director of Goldman, Sachs & Co. and a member of the Wharton Board of Overseers. Mr. Winkelman, who had served as chair since 2011 (Almanac November 1, 2011), remains a member of the Board of Trustees.

Mr. Heyer is CEO and a managing director of Mistral Equity Partners. He has served as chair of the Trustees’ budget and finance committee and he currently serves on the executive, audit & compliance and development committees.

He previously was chair of the Board of Overseers of Penn’s School of Social Policy & Practice and served on the board of the Wharton School.

He serves on the board of directors for Jamba Inc., Worldwise Inc., Hain Celestial Group, XpresSpa, LoveSac, Country  Pure  and Vino Volo.